Literature DB >> 8729554

Factors determining the maintenance dose of warfarin in Chinese patients.

H C Yu1, T Y Chan, J A Critchley, K S Woo.   

Abstract

Chinese patients are reportedly more sensitive than Caucasians to the anticoagulant effect of warfarin. We examined warfarin dose requirements and their determinants in 151 Chinese out-patients on stable maintenance dose of warfarin with international normalized ratio of 2 to 2.5. Mean daily warfarin requirement was 3.3 +/- 1.4 mg, much lower than reported doses in Caucasian patients. The most important determinant was age (r = -0.43, p < 0.001), with progressively lower warfarin requirement with increasing age (p = 0.0001). There was a weaker association with body weight (r = 0.20, p = 0.01). Patients with chronic rheumatic heart disease tended to require a smaller dose than those with heart valve replacements (2.94 +/- 1.24 vs. 3.69 +/- 1.42 mg, p < 0.01). We confirm that Chinese patients require a smaller dose of warfarin for the same degree of anticoagulation. Age is the most important factor affecting dose requirement, although body weight and underlying disease also play a role.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8729554     DOI: 10.1093/qjmed/89.2.127

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  25 in total

Review 1.  Barriers to translating EU and US CVD guidelines into practice in China.

Authors:  Dong Zhao; Dayi Hu
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

2.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Authors:  Nihat Ozer; Nese Cam; Burak Tangurek; Songul Ozer; Huseyin Uyarel; Dilaver Oz; Mehmet Rasit Guney; Figen Ciloglu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

3.  Pharmacogenetics and ethnically targeted therapies.

Authors:  Taslin Rahemtulla; Raj Bhopal
Journal:  BMJ       Date:  2005-05-07

4.  The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

Authors:  Ya-Huei Liou; Chien-Ting Lin; Ying-Jye Wu; Lawrence Shih-Hsin Wu
Journal:  J Hum Genet       Date:  2006-08-19       Impact factor: 3.172

Review 5.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

6.  Ethnic differences in incidence of diseases and response to medicines.

Authors:  Tsung O Cheng
Journal:  J Natl Med Assoc       Date:  2003-05       Impact factor: 1.798

7.  Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

Authors:  Junling Yang; Minxia M He; Wei Niu; Steven A Wrighton; Li Li; Yang Liu; Chuan Li
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 8.  The future of warfarin pharmacogenetics in under-represented minority groups.

Authors:  Larisa H Cavallari; Minoli A Perera
Journal:  Future Cardiol       Date:  2012-07

Review 9.  The need for multicentre cardiovascular clinical trials in Asia.

Authors:  Joey S W Kwong; Cheuk-Man Yu
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

10.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.